Table 1.
Baseline characteristics of all patients
| Characteristic | n (%) |
|---|---|
| General characteristics | |
| All | 175 |
| Female sex | 93 (53.1) |
| Age, years | |
| Mean (SD) | 61.7 (10.3) |
| ASA classification | |
| I–II | 150 (85.7) |
| III | 25 (14.3) |
| Primary tumor characteristics | |
| Location | |
| Colon | 159 (90.9) |
| Rectum | 16 (9.1) |
| Tumor differentiation | |
| Good/moderate | 127 (84.1) |
| Poor | 20 (13.3) |
| Signet cell | 4 (2.6) |
| Tumor histology | |
| Adenocarcinoma | 138 (81.7) |
| Mucinous adenocarcinoma | 31 (18.3) |
| T stage | |
| T1–3 | 107 (61.8) |
| T4 | 66 (38.2) |
| N stage | |
| N0 | 66 (37.9) |
| N1–2 | 108 (62.1) |
| Distant metastases | 13 (7.4) |
| Stage | |
| 1–2 | 62 (35.8) |
| 3–4 | 111 (64.2) |
| Perioperative treatment | |
| Primary tumor: adjuvant chemotherapy | 111 (64.2) |
| Primary tumor: adjuvant chemotherapy type | |
| Oxaliplatin | 2 (1.8) |
| Capecitabine | 4 (3.6) |
| CAPOX | 71 (64.0) |
| FOLFOX | 14 (12.6) |
| 5-FU | 1 (0.9) |
| Unknown | 19 (17.1) |
| Development of PM | |
| ≤ 1, no chemotherapy | 30 (17.1) |
| > 1 year, no chemotherapy | 34 (19.4) |
| ≤ 1 year after chemotherapy | 36 (20.6) |
| > 1 year after chemotherapy | 75 (42.9) |
| HIPEC: neoadjuvant chemotherapy | 21 (12.1) |
| HIPEC: adjuvant chemotherapy | 72 (41.4) |
| Prior surgical score | |
| 0 | 13 (7.6) |
| 1 | 8 (4.7) |
| 2 | 140 (81.9) |
| 3 | 10 (5.8) |
| HIPEC characteristics | |
| Operative procedure | |
| Open CRS and HIPEC | 138 (78.9) |
| Laparoscopic CRS and HIPEC | 3 (1.7) |
| Open–close | 34 (19.4) |
| PCI | |
| Mean (SD) | 12 (8) |
| HIPEC chemotherapy | |
| Mitomycin C | 128 (90.8) |
| Oxaliplatin | 13 (9.2) |
| Resection score | |
| R1 | 135 (77.1) |
| R2a | 6 (3.5) |
| R2b | 34 (19.4) |
| SAE | |
| Total | 94 (53.7) |
| Grade I: mild | 12 (6.9) |
| Grade II: moderate | 35 (20.0) |
| Grade III: severe | 32 (18.3) |
| Grade IV: life-threatening | 13 (7.4) |
| Grade V: death | 2 (1.1) |
| Reoperation | 32 (18.3) |
ASA American Society of Anesthesiologists, CAPOX capecitabine + oxaliplatin, CRS cytoreductive surgery, FOLFOX leucovorin + 5-FU + oxaliplatin, HIPEC hyperthermic intraperitoneal therapy, PCI Peritoneal Cancer Index, PM peritoneal metastases, SAE serious adverse event, SD standard deviation, 5-FU 5-fluorouracil